Twist Bioscience (NASDAQ:TWST - Get Free Report) had its price target cut by equities researchers at JPMorgan Chase & Co. from $40.00 to $33.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an "underweight" rating on the stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 7.07% from the company's current price.
A number of other equities analysts have also recently issued reports on TWST. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Barclays cut their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Finally, Guggenheim set a $50.00 target price on Twist Bioscience in a research note on Friday, March 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and an average price target of $50.40.
Get Our Latest Report on Twist Bioscience
Twist Bioscience Stock Down 5.5 %
Shares of NASDAQ TWST traded down $1.79 during mid-day trading on Tuesday, hitting $30.82. 1,158,651 shares of the stock traded hands, compared to its average volume of 968,895. The stock has a fifty day moving average price of $38.63 and a 200-day moving average price of $43.66. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. Twist Bioscience has a 52 week low of $30.72 and a 52 week high of $60.90.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Research analysts anticipate that Twist Bioscience will post -2.12 EPS for the current year.
Insider Buying and Selling at Twist Bioscience
In other Twist Bioscience news, SVP Paula Green sold 918 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the completion of the sale, the senior vice president now directly owns 130,912 shares of the company's stock, valued at approximately $5,355,609.92. This represents a 0.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Patrick John Finn sold 2,058 shares of the stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the transaction, the chief operating officer now owns 265,460 shares in the company, valued at $10,615,745.40. The trade was a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,991 shares of company stock worth $742,654 in the last three months. 3.01% of the stock is currently owned by company insiders.
Institutional Trading of Twist Bioscience
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Versant Capital Management Inc increased its position in Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after acquiring an additional 580 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares in the last quarter. Van ECK Associates Corp boosted its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience during the third quarter worth $34,000. Finally, Banque Transatlantique SA acquired a new stake in Twist Bioscience in the fourth quarter worth about $43,000.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Read More

Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.